TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01180998

Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A Toric (AOfA)
Description: Soft toric contact lenses for astigmatism

Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A Toric (AOfA)
Description: Soft toric contact lenses for astigmatism

Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A Toric (AOfA)
Description: Soft toric contact lenses for astigmatism

Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A Toric (1DAMfA)
Description: Soft toric contact lenses for astigmatism

Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A Toric (1DAMfA)
Description: Soft toric contact lenses for astigmatism

Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A Toric (1DAMfA)
Description: Soft toric contact lenses for astigmatism
Study: NCT03428737

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Nocturnal controlled pressure control ventilation
Description: use of an inspiratory pressure of 20 cm of H2O and an respiratory frequency chosen to stop all spontaneous breathing activity during the night
Study: NCT04970485

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Talking Matters
Description: Group-level, facilitator-led behavioral intervention for 14-19 year old Black and African American adolescents with an intergenerational component to reduce teen pregnancy, strengthen protective factors to improve optimal health, and increase access to trusted adults.
Study: NCT03428737

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pressure support ventilation
Description: use of a pressure support level identical during the night to the pressure support level at the end of the day.
Study: NCT02640885

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley's cather ballon
Study: NCT02318992

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota
Description: Fecal Microbiota will be delivered via colonoscopy.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota
Description: Fecal Microbiota will be delivered via colonoscopy.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota
Description: Fecal Microbiota will be delivered via colonoscopy.
Study: NCT01832441

Intervention type: OTHER
Group type: OTHER
Intervention: Intra thecal transplantation of autologous MNC
Description: Intra thecal inj.of 100 millions MNC in 3 doses at 7 days interval
Study: NCT01840787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balafilcon A (8.6)
Description: To be worn for 8 hours in one eye, and its comfort compared to another lens on another eye.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balafilcon A (8.3)
Description: To be worn for 8 hours in one eye, and its comfort compared to another lens on another eye.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A
Description: To be worn for 8 hours in one eye, and its comfort compared to another lens on another eye.
Study: NCT02196454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Video with Male or Female Narrator
Description: Participants will watch an educational video about the quadrivalent HPV vaccine (Gardasil) narrated by either a male or female.
Study: NCT04350554

Intervention type: OTHER
Intervention: Pregnancy
Description: To measure and characterize pregnancies and describe the clinical course during pregnancy

Intervention type: OTHER
Intervention: Pregnancy
Description: To evaluate attitudes towards pregnancy (ie. planned pregnancy) and social support among women who become pregnant during the year 2020
Study: NCT04174144

Intervention type: PROCEDURE
Intervention: Single-level TLIF
Description: Transforaminal interbody fusion approach, using polyaxial pedicle screws (Xia®, Stryker Spine, Allendale, NJ, USA), combined with a crescent-shaped interbody cage (T-Plus®, Pioneer Surgical Technology, Marquette, MI, USA), bilateral facet joint removal and laminectomy.
Study: NCT00465725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Picoplatin
Description: The IV dose will be 120 mg/m2. Three oral dose levels will be studied sequentially (6 subjects per dose level) in the absence of dose limiting toxicity 200 mg, 300 mg, or 400 mg total dose.
Study: NCT02425709

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Women will receive oral diclofenac 50 mg 1 hour before the procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Women will receive oral tramadol 50 mg 1 hour before the procedure
Study: NCT04030910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 'LIFEView'
Description: A prototype audiovisual technology in development by Motitech AS.
Study: NCT02131259

Intervention type: DRUG
Intervention: Afatinib dimaleate
Description: 20mg - 50mg
Study: NCT00217399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: Given orally
Study: NCT00093041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zalutumumab
Description: Weekly infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zalutumumab
Description: Weekly infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zalutumumab
Description: Weekly infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zalutumumab
Description: Weekly infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zalutumumab
Description: Weekly infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zalutumumab
Description: Weekly infusion
Study: NCT00519753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%/timolol maleate 0.5% fixed combination ophthalmic solution (DuoTrav)
Description: One drop in study eye(s) once daily in the evening (at 8:00 PM) for 12 weeks
Study: NCT03397069

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Peribulbar block (control)
Description: The Peribulbar block was performed by inserting the needle percutaneously at the area bounded by 1- The imaginary perpendicular line joining inferior lacrimal papilla to the inferior margin of the orbit, laterally 2- Lateral border of the nose, medially 3- Inferior lacrimal canaliculus, superiorly and 4- Inferior orbital margin, inferiorly. The needle was introduced in an anteroposterior direction to its half-length and then in an oblique direction to the optical foramen.~After negative aspiration, 6-8 ml of local anesthetic solution (lidocaine 2%, hyaluronidase 15 IU / ml ) was injected slowly over about 40 seconds or until the appearance of lid fullness. This was followed by a gentle digital massage to the eyeball to facilitate diffusion of the local anesthetic mixture.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peribulbar block(M1)
Description: The Peribulbar block was performed by inserting the needle percutaneously at the area bounded by 1- The imaginary perpendicular line joining inferior lacrimal papilla to the inferior margin of the orbit, laterally 2- Lateral border of the nose, medially 3- Inferior lacrimal canaliculus, superiorly and 4- Inferior orbital margin, inferiorly. The needle was introduced in an anteroposterior direction to its half-length and then in an oblique direction to the optical foramen.~After negative aspiration, 6-8 ml of local anesthetic solution (lidocaine 2%, hyaluronidase 15 IU / ml. plus midazolam 50 µg/ml ) was injected slowly over about 40 seconds or until the appearance of lid fullness. This was followed by a gentle digital massage to the eyeball to facilitate diffusion of the local anesthetic mixture.
Study: NCT02425709

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Women will receive an oral placebo 1 hour before the procedure
Study: NCT03397069

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peribulbar block(M2)
Description: The Peribulbar block was performed by inserting the needle percutaneously at the area bounded by 1- The imaginary perpendicular line joining inferior lacrimal papilla to the inferior margin of the orbit, laterally 2- Lateral border of the nose, medially 3- Inferior lacrimal canaliculus, superiorly and 4- Inferior orbital margin, inferiorly. The needle was introduced in an anteroposterior direction to its half-length and then in an oblique direction to the optical foramen.~After negative aspiration, 6-8 ml of local anesthetic solution (lidocaine 2%, hyaluronidase 15 IU / ml. plus midazolam 100 µg/ml ) was injected slowly over about 40 seconds or until the appearance of lid fullness. This was followed by a gentle digital massage to the eyeball to facilitate diffusion of the local anesthetic mixture.
Study: NCT03837223

Intervention type: DRUG
Intervention: GnRH agonist
Description: In High Responder patients (HR) (more than 18 follicles with diameter ≥ 12mm at ovulation induction), the trigger was obtained with triptorelin 0.2 mg sc. In this cohort if less of 18 oocytes were retrieved, patients were considered at intermediate risk of OHSS and fresh transfer was performed. An adequate support of the luteal phase was initiated: HCG 1500 IU / sc the day of the pick up + estradiol 4 mg + vaginal progesterone 400 mg daily (Rescue protocol).
Study: NCT00910416

Intervention type: DRUG
Intervention: propofol, remifentanil, atracurium
Description: propofol, remifentanil, atracurium dosages are adapted according to clinician's judgment

Intervention type: DRUG
Intervention: propofol, remifentanil, atracurium, sevoflurane
Description: dosages are adapted according to clinician's judgment

Intervention type: DEVICE
Intervention: EEG monitoring
Description: simultaneous monitoring with Bis and Neurosense

Intervention type: DEVICE
Intervention: EEG monitoring
Description: simultaneous monitoring with Bis and Neurosense
Study: NCT04668456

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: the drug administered either subtenon ot iv

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: the drug administered either subtenon ot iv

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lidocaine 2%
Description: subtenon injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine 2%
Description: subtenon injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine 2%
Description: subtenon injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bupivacine 0.5%
Description: subtenon injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacine 0.5%
Description: subtenon injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacine 0.5%
Description: subtenon injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: either subtenon or iv

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: either subtenon or iv
Study: NCT03771664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-217
Description: Administered as capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as capsules.
Study: NCT03703284

Intervention type: OTHER
Intervention: Treatments to reduce intracranial pressure
Description: Drugs such as mannitol, glycerin fructose, etc and/or surgery

Intervention type: OTHER
Intervention: Treatments to reduce intracranial pressure
Description: Drugs such as mannitol, glycerin fructose, etc and/or surgery
Study: NCT02372955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: subjects will be randomly assigned to receive dapagliflozin 10 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimpiride
Description: subjects will be randomly assigned to receive glimpiride 4 mg daily
Study: NCT02726568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: 375 mg Tid (1125 mg per day) until intracranial PD.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SRS
Description: If intracranial PD, then the subjects get stereotatic radiosurgery （30Gy/3f) combined with Icotinib 375mg Tid.
Study: NCT03913520

Intervention type: OTHER
Group type: OTHER
Intervention: Outcome research
Description: patients will undergo an evaluation of their outcome at 30 days postoperatively
Study: NCT02032017

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ceramic on ceramic couple
Description: All patients will get a standard total hip replacement (cementless hydroxyapatite coated cup and a titanium plasmasprayed stem) with a ceramic on ceramic (third generation biolox delta) couple. Preoperative leg length and offset are marked to reconstruct the preoperative leg length and to obtain the optimal offset.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ceramic on ceramic couple
Description: All patients will get a standard total hip replacement (cementless hydroxyapatite coated cup and a titanium plasmasprayed stem) with a ceramic on ceramic (third generation biolox delta) couple. Preoperative leg length and offset are marked to reconstruct the preoperative leg length and to obtain the optimal offset.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous assisted approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterolateral approach

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Both groups will receive usual care (UC) after surgery. This includes standard physiotherapy care consisting of mobilizing and strengthening techniques. All patients will receive a booklet containing information about the surgery, weight bearing after the surgery, and rehabilitation in general.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Both groups will receive usual care (UC) after surgery. This includes standard physiotherapy care consisting of mobilizing and strengthening techniques. All patients will receive a booklet containing information about the surgery, weight bearing after the surgery, and rehabilitation in general.
Study: NCT02454088

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Hydroxylapatite and Triamcinolone acetate
Description: Combination Therapy Triamcinolone acetate and Calcium Hydroxylapatite

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Hydroxylapatite and Placebo
Description: Calcium Hydroxylapatite and Placebo
Study: NCT04284228

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of NEXI-001 T Cells
Description: Procedure: A single IV infusion of NEXI-001 T Cells at Day 1 after Lymphodepletion(LD) Therapy.~At dose Level 1: 1.0 x 108 total viable T cells At dose Level 2: 2.0 x 108 total viable T cells~Procedure: Lymphodepletion: IV administration of fludarabine 30 mg/2 and cyclophosphamide 300 mg/m2 for 3 days.~lymphodepletion (LD) Therapy: Subjects will received bridging therapy agents during lymphodepletion for 3 consecutive days prior to receiving the NEXI-001 product~Drug: Fludarabine~Fludarabine infusion~Other Name: Fludarabine monophosphate~Drug: Cyclophosphamide~Cyclophosphamide infusion~Other Name: Cytoxan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of NEXI-001 T Cells
Description: Procedure: A single IV infusion of NEXI-001 T Cells at Day 1 after Lymphodepletion(LD) Therapy.~At dose Level 1: 1.0 x 108 total viable T cells At dose Level 2: 2.0 x 108 total viable T cells~Procedure: Lymphodepletion: IV administration of fludarabine 30 mg/2 and cyclophosphamide 300 mg/m2 for 3 days.~lymphodepletion (LD) Therapy: Subjects will received bridging therapy agents during lymphodepletion for 3 consecutive days prior to receiving the NEXI-001 product~Drug: Fludarabine~Fludarabine infusion~Other Name: Fludarabine monophosphate~Drug: Cyclophosphamide~Cyclophosphamide infusion~Other Name: Cytoxan
Study: NCT04254003

Intervention type: DEVICE
Group type: OTHER
Intervention: DT1 Toric contact lenses
Description: Delefilcon A contact lenses for the optical correction of astigmatism in people with healthy eyes with or without refractive ametropia (myopia or hyperopia)

Intervention type: DEVICE
Group type: OTHER
Intervention: DT1 Toric contact lenses
Description: Delefilcon A contact lenses for the optical correction of astigmatism in people with healthy eyes with or without refractive ametropia (myopia or hyperopia)

Intervention type: DEVICE
Group type: OTHER
Intervention: AO1DfA contact lenses
Description: Senofilcon A contact lenses for the optical correction of astigmatism in people with healthy eyes with or without refractive ametropia (myopia or hyperopia)

Intervention type: DEVICE
Group type: OTHER
Intervention: AO1DfA contact lenses
Description: Senofilcon A contact lenses for the optical correction of astigmatism in people with healthy eyes with or without refractive ametropia (myopia or hyperopia)
Study: NCT00506363

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulsed dye laser therapy
Description: Each scar will be divided into 3 equal parts. One part will be randomly allocated to be treated with pulsed dye laser and dynamic cooling device on the day of suture removal. Another part will be treated with pulsed dye laser and dynamic cooling device 2 months after suture removal. Only dynamic cooling device will be used for remaining part serving as control. Treatment will repeat for 6 sessions at 3 weeks intervals.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulsed dye laser therapy
Description: Each scar will be divided into 3 equal parts. One part will be randomly allocated to be treated with pulsed dye laser and dynamic cooling device on the day of suture removal. Another part will be treated with pulsed dye laser and dynamic cooling device 2 months after suture removal. Only dynamic cooling device will be used for remaining part serving as control. Treatment will repeat for 6 sessions at 3 weeks intervals.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: pulsed dye laser therapy
Description: Each scar will be divided into 3 equal parts. One part will be randomly allocated to be treated with pulsed dye laser and dynamic cooling device on the day of suture removal. Another part will be treated with pulsed dye laser and dynamic cooling device 2 months after suture removal. Only dynamic cooling device will be used for remaining part serving as control. Treatment will repeat for 6 sessions at 3 weeks intervals.
Study: NCT01686919

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: milk-free
Description: milk-free diet during 8 preoperative weeks
Study: NCT01469169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost (Ventavis inhaled, BAYQ6256)
Description: 2.5 μg or 5.0 μg BAYQ6256 per inhalation session (Inhalation session is to be conducted 6 to 9 times per day with dosing intervals of at least 2 hours.)
Study: NCT01371357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEST 1
Description: 2.4 g/day of guanidinoacetic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEST 2
Description: 2.4 g/day of guanidinoacetic acid + 3.0 g/day of choline dihydrogencitrate + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEST 3
Description: 2.4 g/day of guanidinoacetic acid + 1.6 g/day of betaine HCl + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEST 4
Description: 2.4 g/day of guanidinoacetic acid + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
Study: NCT02933749

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SctO2
Description: The non invasive cerebral oxymetry (INVOS-Covidien) has been used to measure cerebral oxygen saturation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SctO2
Description: The non invasive cerebral oxymetry (INVOS-Covidien) has been used to measure cerebral oxygen saturation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIS
Description: Bispectral index

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIS
Description: Bispectral index
Study: NCT05791708

Intervention type: DRUG
Intervention: Sutimlimab
Description: CAD patients in Sutimlimab cohort must be treated according to routine clinical practice
Study: NCT01544010

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stage-Tailored Manual
Description: Manual with 5 sections for each Stage of change delivered at baseline

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stage-Tailored Manual
Description: Manual with 5 sections for each Stage of change delivered at baseline

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stage-Tailored Manual
Description: Manual with 5 sections for each Stage of change delivered at baseline

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stage-Tailored Manual
Description: Manual with 5 sections for each Stage of change delivered at baseline

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stage Tailored Feedback Report
Description: Tailored printed feedback reports based on assessments of stages of change were delivered at baseline, 6 months and 12 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stage Tailored Feedback Report
Description: Tailored printed feedback reports based on assessments of stages of change were delivered at baseline, 6 months and 12 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stage Tailored Feedback Report
Description: Tailored printed feedback reports based on assessments of stages of change were delivered at baseline, 6 months and 12 months.
Study: NCT00655486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lacosamide
Description: Subjects' dose of lacosamide may be increased or decreased as needed to maintain a subject's effective and tolerable dose during the study. Tablets are 50 mg or 100 mg each; Dose is 100 mg/day up to 800 mg/day administered twice daily throughout the study (up to 2 years).
Study: NCT01057498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RNS60
Description: RNS60, 4ml nebulized twice daily for 15 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RNS60 - single dose
Description: RNS60, single 4 ml dose nebulized for 15 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RNS60 - single dose
Description: RNS60, single 4 ml dose nebulized for 15 minutes
Study: NCT00402038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC Methylnaltrexone
Description: Dose 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SC Placebo